Auszug
Hauptgruppen der Immuntherapeutika sind Zytokine (Interferone, koloniestimulierende Faktoren) und Immunsuppressiva. Betainterferone werden in weiter steigendem Umfang zur Behandlung der multiplen Sklerose eingesetzt, Alfainterferone vor allem bei der Hepatitis C. Hauptindikation der Immunsuppressiva ist die Prophylaxe von Abstoßungsreaktionen bei transplantierten Patienten.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J (2003): Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatol 38: 645–652.
Dunn CJ, Goa KL (2000): Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 59: 681–717.
Ernst E, Schmidt K, Steuer-Vogt MK (2003): Mistletoe for cancer? A systematic review of ranomised clinical trials. Int J Cancer 107: 262–267.
Goodin DS (2001): Interferon-β therapy in multiple sclerosis: evidence for a clinically relevant dose response. Drugs 61: 1693–1703.
Hohenberger P, Reichardt P, Stroszczynski C, Schneider U, Hossfeld DK (2003): Gastrointestinale Stromatumoren-Tumorentität und Therapie mit Imatinib. Dtsch Ärztebl 100: A1612–A1618.
Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kienle H (2003): Mistletoe in cancer. A systematic review on controlled clinical trials. Eur J Med Res 8: 109–119.
Kienle GS, Kiene H (2004): Klinische Studien zur Misteltherapie onkologischer Erkrankungen. Dtsch Zeitschr Onkol 36: 17–24.
Kleeberg UR, Suciu S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) (2004): Final results of the EORTC 18871/ DKG 80-1 randomised phase III trial. rIFN-α2b versus rIFN-γ versus ISCADOR® versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 40: 390–402.
Munari L, Lovati R, Boiko A (2004): Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(1):CD004678.
Peggs K, Mackinnon S (2003): Imatinib Mesylate-The new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348: 1048–1050.
Rieckmann P, O’Connor P, Francis GS, Wetherill G, Alteri E (2004): Haematological effects of interferon-β-1a (Rebif®) therapy in multiple sclerosis. Drug Safety 27: 745–756.
Scheer R, Bauer R, Becker H, Berg PA, Fintelmann V (2001): Vorwort S. V. In: Scheer R. et al. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik, KVC, Essen.
Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J, Hennig M, Lenarz T, Arnold W (2001): The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37: 23–31.
Stupp R, Mason WP, van den Bent MJ, Weiler M, Fisher B, Taphoorn MJ et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005): Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Jens Zeller, W. (2008). Immuntherapeutika und Zytostatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_31
Download citation
DOI: https://doi.org/10.1007/978-3-540-72548-0_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72547-3
Online ISBN: 978-3-540-72548-0
eBook Packages: Medicine (German Language)